 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does atenolol increase the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does atenolol increase the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ATENOLOL increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"relevant_search_extracts"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m ± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on the risk of hip fracture."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on the risk of hip fracture."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ATENOLOL increases or decreases the risk of hip fracture.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for ATENOLOL does not contain information regarding its effect on the risk of hip fracture.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ATENOLOL does not contain information regarding its effect on the risk of hip fracture, hence there is no known increase or decrease in risk associated with ATENOLOL based on FDA [0m
[32mlabel data.[0m
